CLINICAL AND FUNCTIONAL INDICATORS OVER TIME IN OVERWEIGHT PATIENTS WITH BRONCHIAL ASTHMA RECEIVING STANDARD THERAPY VS. STANDARD THERAPY WITH A COMPLEX OF REHABILITATION MEASURES

Keywords: bronchial asthma, overweight, clinical and functional indicators, treatment efficacy

Abstract

The combination of bronchial asthma and obesity leads to increased severity of bronchial asthma course and poorer control level, the development of resistance to basic therapy, and increased frequency of hospitalizations. Modern approaches to the treatment of bronchial asthma and obesity suggest that more attention should be paid to comprehensive rehabilitation programs using methods aimed at all pathogenesis stages of this combination of diseases.

Objective: to analyze changes in clinical and functional indicators over time in overweight patients with bronchial asthma receiving standard therapy vs. standard therapy with a complex of rehabilitation measures

Materials and methods. The study involved 102 overweight patients (body mass index (BMI) ≤ 39.9 kg/height, m2) with persistent asthma of moderate severity aged 35–60 years. The patients were divided into 2 groups. Group I included 72 patients receiving standard pharmacologic therapy (budesonide 160 μg and formoterol 4.5 μg) along with a diet close to the Mediterranean diet, as well as a complex of rehabilitation measures, which included Buteyko breathing technique plus respiratory gymnastics and dosed walking. Group II (30 patients) received only standard pharmacologic therapy along with a diet close to the Mediterranean diet. The duration of the therapy was 6 months. All patients underwent general clinical studies, spirometry, the 6-minute walk test (6MWT) with dyspnea assessment according to the Borg Dyspnoea Scale, surveys using the Asthma Control Questionnaire-5, St George's Respiratory Questionnaire (SGRQ), Beck Depression Inventory, and Spielberger–Khanin Anxiety Inventory.

Results. It was found that the patients receiving treatment along with physical rehabilitation measures presented with more pronounced positive changes, so the indices of FVC and 6MWT medians in Group I were 6 times and 2.4 times higher, respectively. The changes in ACQ5, SGRQ, BDI, and SAI-t score medians in Group I were also more prominent and exceeded the values in Group II by 1.8 times, 4.4 times, 2.5 times, and 3.5 times, respectively.

Conclusions. Inclusion of physical rehabilitation measures, i.e. Buteyko breathing technique, respiratory gymnastics, and dosed walking, contributes to a significant increase in FEV1 and statistically significant improvement in quality of life and psychological status after 6 months of therapy.

Author Biography

Julia A. Zaikina, Department of Tuberculosis, Pulmonology and Family Medicine, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine

Postgraduate Student of the Department of Tuberculosis, Pulmonology and Family Medicine, Kharkiv Medical Academy of Postgraduate Education, 58, Amosov str, Kharkiv, 61176

E-mail: julia.ua.h@gmail.com

ORCID: https://orcid.org/0000-0002-9337-863X

Tel.:+380630509226

 

 

References

1. 2020 GINA Main Report – Global Initiative for Asthma (2020). Available at: https://ginasthma.org/gina-reports. Last accessed:24.04.2021
2. Feshchenko YI, Yashina LA, Boyko DM, Gavrisyuk VK, Krakhmalova OA. Аdapted clinical manual based on evidence bronchial asthma. Kiev: National Academy of Medical Sciences of Ukraine, 2020. 127 P
3. Kaplan A, Boven J, Ryan D, Tsiligianni I, Bosnic-Anticevich S. GINA 2020: Potential Impacts, Opportunities, and Challenges for Primary Care. J. Aller. Clin. Im. 2021; 9 (4): 1516–1519. https://doi.org/10.1016/j.jaip.2020.12.035.
4. Jones SC, Mullan J. Asthma self management in adults: a review of current literature. Col. R of Nur. Aust. 2014; 21(1): 33–41
5. World Health Organization -The top 10 causes of death (2020) Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Last accessed: 09.12.2020
6. Brodskaya O.N, Belevsky AS. Factors of achieving control of bronchial asthma: a global and personalized approach. Pract. Pulm. 2016 46:3-8.
7. Lebedeva OD, Bokova IA, Mikhailov VI, Lebedev GA, Usmonzoda DU. Modern complex technologies for assessing the psychophysiological state of patients and predicting the effectiveness of rehabilitation measures. B. Neur. Psych. Neurosurg. 2016;7: 21-28.
8. Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. J. Appl. Physiol. 2010;108.(2): 206–211.
9. Gomez-Llorente MA, Romero R, Chueca N, Martinez-Cañavate A, Obesity and Asthma: A Missing Link. Int J Mol Sci. 2017; 18(7): 1490. https://doi.org/10.3390/ijms18071490
10. Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P, Dienz O, Irvin CG. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. AJCMED.2012;186(7):598–605. https://doi.org/10.1164/rccm.201203-0573OC
11. Jenny VG, Dolores M, Alexis H, García1 B. Metabolic Syndrome and Asthma. Rec. Pat. Met. & Im. Dr. Disc. 2014; 8:60-66.
12. Kaplan A, Szefler SJ, Halpin D. Impact of comorbid conditions on asthmatic adults and children. NPJ Resp. Med. 2020;30(1):36. https://doi.org/10.1038/s41533-020-00194-9
13. McNeill JN, Lau ES, Zern EK, Nayor M, Malhotra R, Liu EE. Association of obesity-related inflammatory pathways with lung function and exercise capacity. Respiratory medicine. 2021; Volume 183, 106434. https://doi.org/10.1016/j.rmed.2021.106434
14. Littleton SW, Tulaimat A. The effects of obesity on lung volumes andoxygenation. Respiratory medicine.2017;124:15–20. https://doi.org/10.1016/j.rmed.2017.01.004.
15. Rio-Navarro В, Cisneros-Rivero M, Exercise induced bronchospasm in asthmatic andnon asthmatic obese. Allergol. Immunopathol. 2000;28(1): 5-11.
16. Shore SA. Obesity and asthma: location, location, location. ERJ. 2013; 41( 2) :253-254.
17. Pertseva TA, Asthma and obesity: what is the relationship? Ukr.Pulm.Jour. 2011;(1): 61-64.
18. Timchenko AA, Kochuyeva MN, Ruban LA, Zaikina YA. Kharkiv Medical Academy of Postgraduate Education. Method of treatment of patients with cardiopulmonary pathology. Utility model patent. Ukraine (19) ua (11) 144051 (13) u/ (51) IPC (2020.01) A61K 31/00 A61H 23/00 A61P 9/00 A61P 11/00. publication of information on the grant of a patent:25.08.2020, Bul. No. 16.
19. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A. Standardisation of spirometry. ERJ. 2005;26(2): 319–338.
20. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC. An official European Respiratory Society /American Thoracic Society technical standard: field walking tests in chronic respiratory disease. ERJ. 2014; 44(6):1428–1446. https://doi.org/10.1183/09031936.00150314
21. Ramos-Favaretto FS, Fukushiro AP, Scarmagnani RH. Borg scale: a new method for hypernasality rating. Escala de Borg: um novo método para avaliação da hipernasalidade de fala. CoDAS. 2019: 31(6), e20180296. https://doi.org/10.1590/2317-1782/20192018296
22. Juniper EF. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory medicine. 2005;99(5):553-554. doi:10.1016/j.rmed.2004.10.008
23. St. George's University of London. St. George's Respiratory Questionnaire. Retrieved from: http://www.healthstatus.sgul.ac.uk/sgrq
24. Olenskaya TL, Nikolaeva AG, Soboleva LV. Rehabilitation in pulmonology: an educational and methodological manual / Vitebsk: VSMU, 2016.142 p. ISBM 978-985-466-870-3.
25. Yubitskaya NS, Antonyuk MV. Current Issues of Non-Medicated Treatment of Patients with Bronchial Asthma and Obesity. Bul. Phys. Pathol. Resp. 2019;73:87–97. https://doi.org/10.36604/1998-5029-2019-73-87-97.
Published
2021-09-29
How to Cite
Julia A. Zaikina. (2021). CLINICAL AND FUNCTIONAL INDICATORS OVER TIME IN OVERWEIGHT PATIENTS WITH BRONCHIAL ASTHMA RECEIVING STANDARD THERAPY VS. STANDARD THERAPY WITH A COMPLEX OF REHABILITATION MEASURES. Eastern Ukrainian Medical Journal, 9(3), 268-274. https://doi.org/10.21272/eumj.2021;9(3):268-274